Navigation Links
EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
Date:1/23/2008

(endometrium). The American Cancer Society estimates that there will be approximately 39,000 new cases of cancer of the uterine body diagnosed in the U.S. in 2007, resulting in approximately 7,400 deaths. There are currently four basic types of treatment for endometrial cancer including surgery, radiation, hormone therapy, and chemotherapy, of which surgery is the most common treatment.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forw
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
8. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... BEIJING , Oct. 30, 2014 China ... "Company"), a leading fully integrated plasma-based biopharmaceutical company in ... Company plans to release third quarter 2014 financial results ... The Company,s management will hold a ... November 6, 2014, which is 8:30 p.m., Beijing Time ...
(Date:10/30/2014)...  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced an upcoming presentation highlighting its ... The presentation, titled, "Drug Conjugates Bind Covalently to ... Sant P. Chawla , M.D., F.R.A.C.P., Director ... of the Company,s ongoing global, pivotal Phase 3 ...
(Date:10/30/2014)... 2014 Extensiv hydrolysierte ... von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ist ... und Kleinkindern. Der bisher übliche Umgang mit ... Babys bzw. deren stillenden Mütter Milchproteine zu ... bei einer beträchtlichen Anzahl von Kindern der ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... -- Concord Medical Services Holdings Limited ("Concord Medical" ... of the largest network of radiotherapy and diagnostic imaging centers ... the third quarter ended September 30, 2011. ... were RMB124.7 million ($19.6 million)(A) in the third quarter 2011, ...
... -- Nephros, Inc. (OTC Bulletin Board: NEPH ) ... 30, 2011. Recent Highlights ... to be exercised; Received initial review questions from FDA ... Financial Performance for the Third ...
Cached Medicine Technology:Concord Medical Reports Third Quarter 2011 Financial Results 2Concord Medical Reports Third Quarter 2011 Financial Results 3Concord Medical Reports Third Quarter 2011 Financial Results 4Concord Medical Reports Third Quarter 2011 Financial Results 5Concord Medical Reports Third Quarter 2011 Financial Results 6Concord Medical Reports Third Quarter 2011 Financial Results 7Concord Medical Reports Third Quarter 2011 Financial Results 8Concord Medical Reports Third Quarter 2011 Financial Results 9Concord Medical Reports Third Quarter 2011 Financial Results 10Concord Medical Reports Third Quarter 2011 Financial Results 11Concord Medical Reports Third Quarter 2011 Financial Results 12Concord Medical Reports Third Quarter 2011 Financial Results 13Concord Medical Reports Third Quarter 2011 Financial Results 14Concord Medical Reports Third Quarter 2011 Financial Results 15Nephros Reports Third Quarter 2011 Financial Results 2Nephros Reports Third Quarter 2011 Financial Results 3Nephros Reports Third Quarter 2011 Financial Results 4Nephros Reports Third Quarter 2011 Financial Results 5
(Date:10/30/2014)... (HealthDay News) -- When it comes to heart disease, a ... delay care when they have symptoms that spell trouble. ... hospital with a more severe or advanced stage of heart ... Catherine Kreatsoulas, a Fulbright Scholar and research fellow at the ... from the Heart and Stroke Foundation of Canada. In ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, ... bad for your health, a new study reports. Previous ... strengthen bones and prevent osteoporosis. These benefits to bone health ... of a healthy diet. But this new study found ... or women from bone fractures, and was linked to an ...
(Date:10/30/2014)... 2014 (HealthDay News) -- Americans, opinions about the Affordable ... new study finds. Democratic voters are strongly in ... the researchers. Almost three-quarters of Democrats want the next ... want Congress to implement the current law, while 44 ... Among Independent voters, one-third want the law repealed, ...
(Date:10/30/2014)... – A new standard of care for children facing ... multi-year study published in the latest edition of the ... research, led by John Wagner, Jr., M.D., director of ... University of Minnesota and a researcher in the Masonic ... with acute leukemia and myelodysplastic syndrome who received transplants ...
(Date:10/29/2014)... study has found that certain prostate cancer medications are ... causes in men with congestive heart failure or prior ... findings will help doctors and patients weigh the benefits ... therapy (ADT), which reduces levels of male hormones in ... is a mainstay of treatment for prostate cancer. Despite ...
Breaking Medicine News(10 mins):Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... month long fund raising events to find the cure, ... officially declared November as Tay-Sachs Awareness Month,and encourages all ... the need for research to help find a cure. ... frequently in Ashkenazi Jews, French,Canadians, Louisiana Cajuns, and Irish ...
... breakdown, in the epidermis , , FRIDAY, Nov. 2 (Health ... the biological mechanism by which stress increases susceptibility to ... the basis of the stress," said study author Dr. ... of California, San Francisco, and the VA Medical Center, ...
... Mammography Van Features ... NovationDR Digital System, MALVERN, Pa., Nov. 2 ... digital mammography,system in the U.S. The MAMMOMAT(R) NovationDR, a ... Nevada Cancer Institute,s,(NVCI) new Hope Coach, a mobile digital ...
... Emotional Intelligence could be defined as the capacity to perceive, ... so as to be able to distinguish between emotions and ... actions. One of the important benefits of developing this type ... with others and to face an ever changing social and ...
... LAUREL, N.J., Nov. 2 MedQuist Inc. (Pink,Sheets: MEDQ) ... its,previously-disclosed review of strategic alternatives for the Company, is,evaluating ... best interests of the,Company and its shareholders, in light ... ("Philips") of its decision to proceed,with the sale of ...
... Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today ... designation awarded to PI-88 for the,prevention of tumour ... in order to commence the Phase 3 program ... continue with the Special Protocol,Assessment process. The ...
Cached Medicine News:Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 2Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 3Health News:Stress Robs Skin of Antimicrobial Defenses 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 3Health News:Emotional Intelligence and the use of tobacco and cannabis 2Health News:MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 3
... a product comes along that forever raises ... category. The new StealthStation TREON plus Treatment ... Built on the phenomenal success of the ... system in the worldthe new TREON plus ...
... the DigiCat Imager ("DCI") to provide rapid, ... The DCI can measure the cataract and ... objective, appropriate and timely surgical decision can ... technology is especially useful in todays healthcare ...
... Until recently, most patients with age-related macular ... to improve or stabilize with or without ... Lumenis has revolutionized the standard of care ... the Opal Photoactivator especially for use in ...
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
Medicine Products: